Duloxetine in the Treatment of Women with Urinary Incontinence: A Systematic Review and Meta-analysis of Efficacy Data from Randomized Controlled Clinical Trials

Mangır, Naşide; Uçar, Murat; Gülpınar, Ömer; Özkürkçügil, Cüneyd; Demirkesen, Oktay; Tarcan, Tufan

doi:10.4274/jus.galenos.2022.2022.0027

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is essential to underscore the significance of neurological pathways in treating SUI. This fact could be reiterated by observing the relative success of duloxetine and other antidepressants [ 21 , 44 ]. Interestingly, studies on female athletes have shown that those experiencing SUI during practice report fewer incontinence episodes during competition.…”

Section: Discussionmentioning

confidence: 99%

Pharmacotherapy in Stress Urinary Incontinence; A Literature Review

Tabei,

Baas,

Mahdy

2024

Curr Urol Rep

View full text Add to dashboard Cite

Purpose of Review Stress urinary incontinence (SUI) is a commonly observed condition in females, as well as in males who have undergone prostatectomy. Despite the significant progress made in surgical techniques, pharmacotherapy has not yielded substantial outcomes within the clinical domain. This review aims to present a comprehensive overview of the existing pharmacotherapy options for stress urinary incontinence (SUI) and the emerging therapeutic targets in this field. Recent Findings One meta-analysis demonstrated that α-adrenergic medications are more efficacious in improving rather than curing SUI symptoms. One trial showed reduced pad weight gain with PSD-503, a locally administered α-adrenergic receptor agonist. New data show that duloxetine’s risk outweighs its benefits. One small-scale trial was found to support the use of locally administered estriol in improving subjective outcomes. Emerging targets include serotonin 5HT2C agonists, selective inhibitors of norepinephrine uptake, and myostatin inhibitors. Summary Only one of the evaluated drugs, duloxetine, has been approved by some countries. Currently, trials are evaluating novel targets. Systemic adverse effects such as gastrointestinal upset with duloxetine and orthostatic hypotension with α-adrenoceptor agonists have hampered the efficacy of drugs used to treat SUI in women and men.

show abstract

Section: Discussionmentioning

confidence: 99%